Lisandra Muñoz-Hidalgo1, Teresa San-Miguel2, Javier Megías2, Eva Serna3, Silvia Calabuig-Fariñas2,3,4,5,6, Daniel Monleón2, Rosario Gil-Benso2, Miguel Cerdá-Nicolás1,2, Concha López-Ginés2. 1. INCLIVA, Clinic Hospital of Valencia, 46010 Valencia, Spain. 2. Department of Pathology, Faculty of Medicine and Dentistry, University of Valencia, 46010 Valencia, Spain. 3. Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, 46010 Valencia, Spain. 4. Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), 28029 Madrid, Spain. 5. Molecular Oncology Laboratory, Fundación Hospital General Universitario de Valencia, 46014 Valencia, Spain. 6. TRIAL Mixed Unit, Centro de Investigación Príncipe Felipe-Fundación para la Investigación del Hospital Ge-neral Universitario de València, 46012 Valencia, Spain.
Abstract
Migration of glioblastoma cells into surrounding tissue is one of the main features that makes this tumor incurable. We evaluated whole-genome miRNA expression profiling associated with different EGFR amplification patterns in 30 cases of primary glioblastoma. From the 64 miRNAs that showed differential expression between tumors with a high level of EGFR amplification and tumors without EGFR amplification, 40% were related with cell migration, being miR-200c the most differentially expressed between these two groups. We investigated the effect of miR-200c on ZEB1 expression and cell migration in an in vitro transfection model with a miR-200c mimic, a miR-200c inhibitor and siRNA targeting EGFR in three short-term cultures with different levels of EGFR amplification obtained from resected glioblastomas. The cell culture with the highest EGFR amplification level presented the lowest miR-200c expression and the status of EGFR modulated the effect of miR-200c on ZEB1 expression. Silencing EGFR led to miR-200c upregulation and ZEB1 downregulation in transfected cultures, except in the presence of high levels of EGFR. Likewise, miR-200c upregulation decreased ZEB1 expression and inhibited cell migration, especially when EGFR was not amplified. Our results suggest that modulating miR-200c may serve as a novel therapeutic approach for glioblastoma depending on EGFR status.
Migration of glioblastoma cells into surrounding tissue is one of the main features that makes this n class="Disease">tumor incurable. We evaluated whole-genome miRNA expression profiling associated with different EGFRamplification patterns in 30 cases of primary glioblastoma. From the 64 miRNAs that showed differential expression between tumors with a high level of EGFRamplification and tumors without EGFRamplification, 40% were related with cell migration, being miR-200c the most differentially expressed between these two groups. We investigated the effect of miR-200c on ZEB1 expression and cell migration in an in vitro transfection model with a miR-200c mimic, a miR-200c inhibitor and siRNA targeting EGFR in three short-term cultures with different levels of EGFRamplification obtained from resected glioblastomas. The cell culture with the highest EGFRamplification level presented the lowest miR-200c expression and the status of EGFR modulated the effect of miR-200c on ZEB1 expression. Silencing EGFR led to miR-200c upregulation and ZEB1 downregulation in transfected cultures, except in the presence of high levels of EGFR. Likewise, miR-200c upregulation decreased ZEB1 expression and inhibited cell migration, especially when EGFR was not amplified. Our results suggest that modulating miR-200c may serve as a novel therapeutic approach for glioblastoma depending on EGFR status.
Authors: Ulf D Kahlert; Abigail K Suwala; Eric H Raabe; Florian A Siebzehnrubl; Maria J Suarez; Brent A Orr; Eli E Bar; Jaroslaw Maciaczyk; Charles G Eberhart Journal: Brain Pathol Date: 2015-02-08 Impact factor: 6.508
Authors: Emily L Paterson; Natasha Kolesnikoff; Philip A Gregory; Andrew G Bert; Yeesim Khew-Goodall; Gregory J Goodall Journal: ScientificWorldJournal Date: 2008-09-21
Authors: Laura J Lewis-Tuffin; Fausto Rodriguez; Caterina Giannini; Bernd Scheithauer; Brian M Necela; Jann N Sarkaria; Panos Z Anastasiadis Journal: PLoS One Date: 2010-10-27 Impact factor: 3.240